ANSiscope

Contents
1 Problem being addressed
2 Detailed description of the solution
3 Designed by
4 When and where it was tested/implemented
5 Funding Source
6 References
   6.1 Peer-reviewed publication
   6.2 Internally generated reports
   6.3 Externally generated reports

Problem being addressed

Diabetic autonomic neuropathy (DNS) is a common complication of diabetes that affects between 40 and 60 percent of patients (DyAnsys, n.d.). It is a silent killer, which if left untreated can kill within 5 years. There is very little diagnosis of this disease in the developing world.

Detailed description of the solution

This device is safe, noninvasive, and uses a portable electrocardiogram (ECG) to measure the activity of the autonomic nervous system (ANS) hence the name ANSiscope. It detects the percentage of autonomic dysfunction. The initial reading takes approximately one minute to show on the device and each reading is updated after each subsequent heartbeat. Different stages of diabetic autonomic neuropathy are indicated on the device: healthy, early, late, advanced and most advanced. The device comes with a battery and a charger, allows for data storage on a USB and can be linked to a printer.
Designed by

- Designed by: Dyansys, Inc.
- Manufacturer location: San Mateo, California, United States

When and where it was tested/implemented

This device is sold in South Africa and clinical trials were conducted in India.

Funding Source

This device receives private and commercial funds.

References

Peer-reviewed publication


Internally generated reports


Externally generated reports